Dr. Benoit Arsenault obtained his Ph.D. in Physiology-Endocrinology from Université Laval in Québec City, Canada in 2009. After two postdoctoral fellowships at the Academic Medical Center in Amsterdam and at the Montreal Heart Institute, Dr. Arsenault joined the Department of Medicine of Université Laval in 2013. He is also a research scientist in the cardiology axis at the Québec Heart and Lung Institute.

In research projects funded by the Canadian Institutes of Health Research (CIHR), Dr. Arsenault’s team use genetic tools such as Mendelian randomization and family studies to investigate the causes and consequences of cardiometabolic diseases such as non-alcoholic fatty liver disease, dyslipidemia, type 2 diabetes and cardiovascular diseases. He also leads other research programs funded by the CIHR on the basic and genetic mechanisms through which Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 (PCSK9) contribute to heart valve disorders such as calcific aortic valve stenosis using multi-omic technologies.

Dr. Arsenault holds a junior scholar award from the Fonds de recherche du Québec: Santé (FRQS) and his research is also funded by the Foundation of the Québec Heart and Lung Institute. Dr. Arsenault has authored or co-authored more than 130 peer-reviewed manuscripts in the field of lipoprotein-lipid research and of the genetics of heart valve diseases and cardiometabolic diseases.


Lifestyle and prevention: how do we define success?89th EAS Congress 2021(TreatmentDietsExercise)